Wolfram E Samlowski

20030003074, Jan 2, 2003

Jun 13, 2002

10/172805

Gaylen Zentner - Salt Lake City UT, US
Miroslav Baudys - Sandy UT, US
Maria Jurek - Sandy UT, US
Wolfram Samlowski - Salt Lake City UT, US

MacroMed, Inc.

A61K038/20
A61K009/14

424/085200, 424/486000

Therapeutic formulations comprising an effective amount of IL-2 or other lymphokine and a biodegradable polymeric carrier having reverse gelation properties and the methods of use thereof for local or both local and systemic control of proliferative cell disorders are disclosed. The formulation can be administered intratumorally/peritumorally and forms an IL-2 containing depot. The IL-2-containing depot provides for continuous, prolonged release of IL-2 sufficient to stimulate the production of cytotoxic T lymphocytes which function both locally and systemically, without causing unacceptable side effects.

20060159657, Jul 20, 2006

Mar 21, 2006

11/386156

Kirk Fowers - Centerville UT, US
Gaylen Zentner - Salt Lake City UT, US
Miroslav Baudys - Lilburn GA, US
Maria Jurek - Sandy UT, US
Wolfram Samlowski - Salt Lake City UT, US

A61K 38/20
A61K 9/14

424085200, 424486000

Therapeutic formulations comprising an effective amount of IL-2 or other lymphokine and a biodegradable polymeric carrier having reverse gelation properties and the methods of use thereof for local or both local and systemic control of proliferative cell disorders is disclosed. The formulation can be administered intratumorally/peritumorally and forms an IL-2 containing depot. The IL-2-containing depot provides for continuous, prolonged release of IL-2 sufficient to stimulate the production of cytotoxic T lymphocytes which function both locally and systemically, without causing unacceptable side effects.

20060177908, Aug 10, 2006

Mar 8, 2004

10/548153

Wolfram Samlowski - Salt Lake City UT, US
Nathan Adams - Colchester VT, US
John McGregor - Salt Lake City UT, US

C07K 14/54
C07H 21/04
C12P 21/04

435069520, 435320100, 435325000, 530351000, 536023500

Compounds, genetic constructs, and cancer treatment methods are provided. Expression vectors were designed to express fusion genes including hIL-2 with a Fcε-γ transmembrane anchor derived from a subunit of the FC epsilon receptor. mRNA and the IL-2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL-2tm protein on the tumor cell surface membrane was confirmed by microscopy. RD995 cells transfected with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into C3H/HEN mice. Tumors of mice implanted with 10or 10RD995 cells transfected with IL-2tm grew slower than controls. It is believed that selective expression of cytokines such as IL-2 on the surface of tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition and killing, potentially avoiding toxicity associated with known cytokine therapies.

20100158857, Jun 24, 2010

May 23, 2007

12/227543

Wolfram Samlowski - Salt Lake City UT, US
Muralidhar Kondapaneni - Salt Lake City UT, US
John McGregor - Salt Lake City UT, US

A61K 38/20
A61K 31/198
A61K 31/221
A61K 31/155
A61K 31/416
A61K 31/17
A61K 31/195
A61P 35/00

424 852, 514565, 514551, 514634, 514406, 514580, 514562, 514561

The present invention relates to the treatment and prevention of the toxic effects associated with increased nitric oxide synthase activity in endothelial cells. In particular, the present invention relates to compounds and methods of treatment that inhibit the nitric oxide synthases present in endothelial cells and methods for treating diseases using such compounds and methods.

20160153047, Jun 2, 2016

Nov 14, 2013

14/080759

Wolfram E. Samlowski - Las Vegas NV, US

TrueCells, LLC - Las Vegas NV

C12Q 1/68
C12N 5/09

Cell culture isolation and expansion of CTC from cancer patients to derive prognostic and predictive information and provide a substrate for subsequent genetic, metabolic, immunologic and other cellular characterizations. This method isolates and extracts CTC from a blood sample to grow cancer cell colonies for a long-term tumor repository, tumor biology and pharmacogenomics research. Following removal of small numbers of contaminating host cells, this method will assist with detection of single nucleotide changes in cancer cells to direct treatment, provide global screening for mutations in oncogenes or tumor suppressor genes, and provide a minimally invasive biopsy technique that may allow reassessment of tumors after treatment failures. This method provides an RNA expression screen at a single locus or a genomic level and allow identification of signaling pathways, provide an evaluation of key protein expression to study their metabolic pathways, and provide individual or global screened miRNA molecules.